Advances In The Treatment Of Advanced Non-small Cell Lung Cancer With Antiangiogenic Drugs Combined With Immune Checkpoint Inhibitors

The treatment of advanced non-small cell lung cancer(NSCLC)is a major clinical problem.The clinical drug treatment programs include single drug therapy and drug combination therapy with different mechanisms.The drug combination therapy programs include the combination of different chemotherapy drugs,as well as the combination of chemotherapy drugs with angiogenesis inhibitors,targeting agents,immune checkpoint inhibitors and other drugs,But it has not achieved the ideal clinical effect.In recent years,immunosuppression has achieved encouraging results in the treatment of a variety of solid tumors,which has benefited the survival of some patients.Studies have shown that angiogenesis inhibitors can reverse the immunosuppressive state of tumor microenvironment,and have synergistic effect in anti-tumor therapy when combined with immune checkpoint inhibitors.In the clinical research of malignant tumors such as liver cancer,gastric cancer,renal cancer and melanoma,whether the use of immune checkpoint inhibitors combined with anti angiogenic monoclonal antibodies or combined with anti angiogenic small molecule TKI drugs can benefit the patients with advanced stage in terms of objective response rate,progression free survival and overall survival,and the tolerance of combined drugs is acceptable,It is expected to break through the survival bottleneck of advanced lung cancer treatment.Because of the good synergistic mechanism of the two drugs,the research on the combined treatment of advanced lung cancer is also in progress,aiming to find a more suitable combination of drugs and suitable population.Therefore,this article reviews the theoretical basis of anti-tumor angiogenesis therapy,immune checkpoint inhibitor therapy and their combination therapy,as well as the clinical research progress in advanced non-small cell lung cancer.